72.55↑0.20 (0.28%)
03:49 PM,26th Sep 202373.83↑1.83 (2.54%)
04:01 PM,26th Sep 2023BSE : 532878
NSE : ALPA
Sector : Health care
ISIN Code : INE385I01010
Last Updated: Sep 26 2023 | 04:01 PM IST
Market Cap (₹ Cr) | 152 |
Turnover (₹ Cr) | 0.04 |
Volume (Shares) | 60873 |
Face Value | 10 |
52-WK High | 85.90 |
52-WK High Date | 19 Jan 2023 |
52-WK Low | 49.00 |
52-WK Low Date | 21 Nov 2022 |
All Time High | 108.80 |
All Time High Date | 20 Jan 2022 |
All Time Low | 5.10 |
All Time Low Date | 13 Jun 2013 |
Mr. Purushottam R. Patel Mr. M.S. Chawla and Mr. Pravin C. Shah partners of M/s Alpa Laboratories which was formed in the year 1967 incorporated a private limited company in the name of Alpa Laboratories Private Limited on March 18 1988 for manufacture of pharmaceutical formulations. In the year 1998 Alpa Laboratories Private Limited was converted into a public limited company with effect from September 3 1998 with the name of 'Alpa Laboratories Limited'.In the year 1997 the company has initiated setting of a new manufacturing unit at Rau(Indore District) Madhya Pradesh. The unit commenced commercial production in the year 1999 of all types of formulations viz. Injectables (Vials/Ampoules both liquid and Dry) tablets capsules eye/ear drops ointment and creams. The company has manufacture a range of products such as ethical drugs generic drugs over the counter drugs (OTC) and veterinary products in various dosage forms and market them under the trade mark 'Alpa' which is a registered trademark in the name of Alpa Labs (India) Limited a promoter group company. The company has also manufacture formulations for a number of other pharmaceutical companies of national and international repute such as Cipla Zydus Cadila Lupin Glenmark Genom Biotech Jenburkt etc. (under their own brands) located both in India and abroad in countries such as Philippines Iran Iraq Sierra Leon Madagascar Kenya Liberia Puerto Rico Haiti Sudan Ghana Nigeria Srilanka etc. Further the company has also undertaken contract manufacturing of a large variety of pharmaceuticals.The company has manufacture various dosage forms which include injectables (vials / ampoules both liquid and dry) tablets capsules eye / ear drops ointment and creams and dry syrups. The company has an established product-marketing network covering both metro and mini metro cities which enable company to reach the existing and potential customers through the network of distributors and dealers spread across the country. For the purpose of marketing the various products the company's business has been categorized as Branded Generic Division Veterinary Division Exports Division and Contract Manufacturing Division.
PARAMETER | VALUES |
---|---|
Market Cap (₹ Cr) | 152 |
EPS - TTM (₹) [S] | 6.16 |
P/E Ratio (X) [S] | 1.06 |
Face Value (₹) | 10 |
Latest Dividend (%) | - |
Latest Dividend Date | - |
Dividend Yield (%) | - |
Book Value Share (₹) [S] | 68.69 |
P/B Ratio (₹) [S] | 1.06 |
[*C] Consolidated [*S] Standalone |
Scheme Name ↑↓ | Amount Invested ( ₹ Cr ) ↑↓ | No Of Shares ↑↓ | Net Asset (%) ↑↓ |
---|
Date↑↓ | Broker↑↓ | Action↑↓ | Prices(Rs)↑↓ | Report |
---|---|---|---|---|
Data Not Found |
Today's Low/High | 72.00 74.00 |
Week Low/High | 71.80 76.00 |
Month Low/High | 71.75 85.00 |
Year Low/High | 49.00 86.00 |
All time Low/High | 5.50 109.00 |
Period | BSE | NSE | SENSEX | NIFTY |
---|---|---|---|---|
1 Week | -0.70% | -0.82% | -2.44 | -2.33% |
1 Month | -10.52% | -10.21% | 1.63 | 2.07% |
3 Month | 10.21% | 10.09% | 4.71 | 5.35% |
6 Month | 34.48% | 36.24% | 14.63 | 16.05% |
1 Year | 15.34% | 15.34% | 13.51 | 13.49% |
3 Year | 162.86% | 162.86% | 76.38 | 77.96% |
Date | Client Name | Exchange | Transaction | Quantity | Price |
---|---|---|---|---|---|
25-08-2023 | GRAVITON RESEARCH CAPITAL LLP | NSE | SELL | 133673 | 81.58 |
25-08-2023 | GRAVITON RESEARCH CAPITAL LLP | NSE | BUY | 133673 | 81.39 |
19-01-2023 | BRIJESH PAREKH HUF | NSE | SELL | 140000 | 73.90 |
19-01-2023 | CHETAN RASIKLAL SHAH | NSE | BUY | 198193 | 81.13 |
19-01-2023 | CHETAN RASIKLAL SHAH | NSE | SELL | 198193 | 84.56 |
19-01-2023 | MUDUPULAVEMULA SURENDRANADHA REDDY | NSE | BUY | 154336 | 81.19 |
19-01-2023 | MUDUPULAVEMULA SURENDRANADHA REDDY | NSE | SELL | 154336 | 81.33 |
19-01-2023 | MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED | NSE | SELL | 124507 | 83.94 |
19-01-2023 | MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED | NSE | BUY | 124507 | 78.98 |
19-01-2023 | NK SECURITIES RESEARCH PRIVATE LIMITED | NSE | BUY | 143863 | 79.46 |
Load More |
Name | Price(In Rs) | Chg(%) | Mkt Cap(Rs Cr) | Sales(Rs Cr) | Profit(Rs Cr) | EPS(Rs) | P/E(x) |
---|
Category | Share(%) |
---|---|
Promoter | 57.29 |
Financial Institutions Banks | 0.01 |
Foreign Institutional Investors | 0.00 |
Insurance Companies | 0.00 |
Mutual Funds Uti | 0.00 |
Other Institutional Investors | 0.00 |
Indian Public | 37.79 |
Others Non Institutional Investors | 4.90 |
Custodians | 0.00 |
Announcement Date | Purpose | From | To | Remarks |
---|---|---|---|---|
Data Not Found |
Search for Price History
Date | Open | High | Low | Close | Shares | Trades |
---|---|---|---|---|---|---|
Data Not Found |
Load more
Chairman & Exec. Director : Mahendra Singh Chawla
Executive Director : Pravin C Shah
Independent Director : Sharad Chand Lunawat
Independent Director : Devendra Baheti
Independent Director : Krishna Das Malani
Managing Director : Paresh Chawla
Independent Director : Jyoti Jain
Company Sec. & Compli. Officer : Swati Bagh
Executive Director : Vitthal Kothana
Additional Director : SUNIL VALECHA
Independent Director : Saket Baheti
Independent Director : Pratibha Lunawat
Registered Office: 33/2 Pigdamber, A B Road Rau,Indore,Madhya Pradesh-453446 Ph: 91-731-4294567
Email:is@alpalabs.com